A Chemogenomic Analysis of Ionization Constants-Implications for Drug Discovery

被引:39
|
作者
Manallack, David T. [1 ]
Prankerd, Richard J. [1 ]
Nassta, Gemma C. [1 ]
Ursu, Oleg [2 ]
Oprea, Tudor I. [2 ]
Chalmers, David K. [1 ]
机构
[1] Monash Univ, Monash Inst Pharmaceut Sci, Parkville, Vic 3052, Australia
[2] Univ New Mexico, Sch Med, Dept Internal Med, Translat Informat Div, Albuquerque, NM 87131 USA
基金
美国国家卫生研究院;
关键词
acidity; basicity; chemogenomics; computational medicinal chemistry; functional groups; ionization constants; NATURAL-PRODUCTS; BINDING; DESIGN; SET; CONSTRUCTION; GENERATION; CHEMISTS; PLASMA; RULES; ADMET;
D O I
10.1002/cmdc.201200507
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Chemogenomics methods seek to characterize the interaction between drugs and biological systems and are an important guide for the selection of screening compounds. The acid/base character of drugs has a profound influence on their affinity for the receptor, on their absorption, distribution, metabolism, excretion and toxicity (ADMET) profile and the way the drug can be formulated. In particular, the charge state of a molecule greatly influences its lipophilicity and biopharmaceutical characteristics. This study investigates the acid/base profile of human small-molecule drugs, chemogenomics datasets and screening compounds including a natural products set. We estimate the acid-ionization constant (pKa) values of these compounds and determine the identity of the ionizable functional groups in each set. We find substantial differences in acid/base profiles of the chemogenomic classes. In many cases, these differences can be linked to the nature of the target binding site and the corresponding functional groups needed for recognition of the ligand. Clear differences are also observed between the acid/base characteristics of drugs and screening compounds. For example, the proportion of drugs containing a carboxylic acid was 20?%, in stark contrast to a value of 2.4?% for the screening set sample. The proportion of aliphatic amines was 27?% for drugs and only 3.4?% for screening compounds. This suggests that there is a mismatch between commercially available screening compounds and the compounds that are likely to interact with a given chemogenomic target family. Our analysis provides a guide for the selection of screening compounds to better target specific chemogenomic families with regard to the overall balance of acids, bases and pKa distributions.
引用
收藏
页码:242 / 255
页数:14
相关论文
共 50 条
  • [1] Thematic Analysis™: A Chemogenomic Approach to GPCR Drug Discovery
    Crossley, Roger
    Macritchie, Jacqueline Anne
    Slater, Martin John
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2011, 11 (15) : 1925 - 1943
  • [2] Chemogenomic approaches to drug discovery - Commentary
    Caron, PR
    Mullican, MD
    Mashal, RD
    Wilson, KP
    Su, MS
    Murcko, MA
    [J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 2001, 5 (04) : 464 - 470
  • [3] Applications of chemogenomic library screening in drug discovery
    Jones, Lyn H.
    Bunnage, Mark E.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (04) : 285 - 296
  • [4] Applications of chemogenomic library screening in drug discovery
    Lyn H. Jones
    Mark E. Bunnage
    [J]. Nature Reviews Drug Discovery, 2017, 16 : 285 - 296
  • [5] Chemogenomic Approaches for Revealing Drug Target Interactions in Drug Discovery
    Bhargava, Harshita
    Sharma, Amita
    Suravajhala, Prashanth
    [J]. CURRENT GENOMICS, 2021, 22 (05) : 328 - 338
  • [6] A chemogenomic approach to drug discovery: focus on cardiovascular diseases
    Cases, Montserrat
    Mestres, Jordi
    [J]. DRUG DISCOVERY TODAY, 2009, 14 (9-10) : 479 - 485
  • [7] Chemogenomic profiling of Plasmodium falciparum as a tool to aid antimalarial drug discovery
    Pradhan, Anupam
    Siwo, Geoffrey H.
    Singh, Naresh
    Martens, Brian
    Balu, Bharath
    Button-Simons, Katrina A.
    Tan, Asako
    Zhang, Min
    Udenze, Kenneth O.
    Jiang, Rays H. Y.
    Ferdig, Michael T.
    Adams, John H.
    Kyle, Dennis E.
    [J]. SCIENTIFIC REPORTS, 2015, 5
  • [8] Chemogenomic approaches to drug discovery: similar receptors bind similar ligands
    Klabunde, T.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2007, 152 (01) : 5 - 7
  • [9] Chemogenomic profiling of Plasmodium falciparum as a tool to aid antimalarial drug discovery
    Anupam Pradhan
    Geoffrey H. Siwo
    Naresh Singh
    Brian Martens
    Bharath Balu
    Katrina A. Button-Simons
    Asako Tan
    Min Zhang
    Kenneth O. Udenze
    Rays H.Y. Jiang
    Michael T. Ferdig
    John H. Adams
    Dennis E. Kyle
    [J]. Scientific Reports, 5
  • [10] Preclinical drug safety analysis by chemogenomic profiling in the liver
    Fielden, MR
    Pearson, C
    Brennan, R
    Kolaja, KL
    [J]. AMERICAN JOURNAL OF PHARMACOGENOMICS, 2005, 5 (03) : 161 - 171